Hyperstat-F Tablet is a combination lipid-lowering agent containing Fenofibrate 160 mg and Rosuvastatin 10 mg, indicated for the management of dyslipidemia and mixed hyperlipidemia. Fenofibrate, a fibric acid derivative, primarily reduces triglyceride levels and increases high-density lipoprotein cholesterol (HDL-C) by activating peroxisome proliferator-activated receptor alpha (PPARα), which enhances lipolysis and elimination of triglyceride-rich particles. Rosuvastatin, a potent HMG-CoA reductase inhibitor, effectively lowers low-density lipoprotein cholesterol (LDL-C) and total cholesterol by inhibiting the rate-limiting step in cholesterol biosynthesis, thereby upregulating LDL receptors and enhancing clearance of LDL particles from the bloodstream. The combination therapy offers a complementary mechanism of action, providing comprehensive lipid control in patients who require both triglyceride reduction and LDL-C lowering. Hyperstat-F is indicated for patients with mixed dyslipidemia, hypertriglyceridemia, and those at high risk of cardiovascular events due to elevated lipid levels. It should be used as an adjunct to diet, exercise, and lifestyle modification. Caution is advised in patients with hepatic or renal impairment, and regular monitoring of liver enzymes and creatine kinase is recommended to detect potential adverse effects such as myopathy or hepatotoxicity. Hyperstat-F should be prescribed under medical supervision to optimize lipid management and reduce cardiovascular risk.